Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

628 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Klareskog L, et al. Among authors: kalden j. Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7. Lancet. 2004. PMID: 15001324 Clinical Trial.
Perspectives for TNF-alpha-targeting therapies.
Lorenz HM, Kalden JR. Lorenz HM, et al. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S17-24. doi: 10.1186/ar564. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110119 Free PMC article. Review.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Smolen JS, et al. Among authors: kalden jr. Arthritis Rheum. 2006 Mar;54(3):702-10. doi: 10.1002/art.21678. Arthritis Rheum. 2006. PMID: 16508926 Clinical Trial.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Antoni CE, et al. Among authors: kalden jr. Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. Arthritis Rheum. 2005. PMID: 15818699 Clinical Trial.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. St Clair EW, et al. Arthritis Rheum. 2004 Nov;50(11):3432-43. doi: 10.1002/art.20568. Arthritis Rheum. 2004. PMID: 15529377 Clinical Trial.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Maini RN, et al. Among authors: kalden jr. Arthritis Rheum. 1998 Sep;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. Arthritis Rheum. 1998. PMID: 9751087 Clinical Trial.
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Maini RN, et al. Among authors: kalden jr. Arthritis Rheum. 2004 Apr;50(4):1051-65. doi: 10.1002/art.20159. Arthritis Rheum. 2004. PMID: 15077287 Clinical Trial.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Maini R, et al. Among authors: kalden j. Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0. Lancet. 1999. PMID: 10622295 Clinical Trial.
628 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page